Table 3.
The results of MMRM analyses: factors associated with EQ-5D scores during follow-up
| Parameter | Parameter estimate | Standard error | P-value |
|---|---|---|---|
| Intercept | 0.850 | 0.030 | <0.001 |
| Age | −0.001 | 0.000 | 0.095 |
| Female (versus male) | −0.022 | 0.008 | 0.009 |
| Region (versus East Asia) | |||
| Mexico | 0.025 | 0.010 | 0.009 |
| The Middle East | −0.028 | 0.012 | 0.019 |
| Others | −0.038 | 0.026 | 0.140 |
| Employment (versus full time) | |||
| Economically inactive | −0.019 | 0.009 | 0.048 |
| Unemployed/part-time | −0.013 | 0.011 | 0.236 |
| Not living in his/her own house | 0.023 | 0.010 | 0.029 |
| EQ-5D index at baseline | 0.087 | 0.015 | <0.001 |
| QIDS-SR16 score at baseline | −0.002 | 0.001 | 0.107 |
| SSI-pain score at baseline | −0.004 | 0.001 | <0.001 |
| Comorbidities (versus none) | |||
| 1 | −0.034 | 0.010 | 0.001 |
| 2+ | −0.113 | 0.018 | <0.001 |
| Had MDD episodes in the 24 months prior to baseline | −0.021 | 0.008 | 0.008 |
| Duloxetine (versus SSRI) | 0.034 | 0.011 | 0.002 |
| Weeks (versus week 8) | |||
| Week 16 | 0.072 | 0.007 | <0.001 |
| Week 24 | 0.117 | 0.008 | <0.001 |
| Weeks × treat | |||
| Duloxetine at week 16 | 0.027 | 0.011 | 0.012 |
| Duloxetine at week 24 | 0.035 | 0.012 | 0.003 |
Abbreviations: EQ-5D, EuroQoL-5 Dimensions; QIDS-SR16, 16-item Quick Inventory of Depressive Symptomatology Self-Report; SSRI, selective serotonin reuptake inhibitor; MMRM, mixed effects modeling with repeated measures; MDD, major depressive disorder; SSI-pain, somatic symptom inventory; QoL, quality of life.